The Latest Cardiac and Vascular News
CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr. Norman Wong is retiring as CSO, effective today. “Dr. Kulikowski has a contributed tremendously since joining Resverlogix in 2005 and we are delighted to […]
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study” in the prestigious American Journal of Respiratory and Critical Care Medicine – which has an impact factor of 21.4. The article […]
Positive Findings in Journal of Alzheimer’s Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe and Effective Therapeutic for Vascular Cognitive Impairment Apabetalone is a First-in-Class Oral Epigenetic Therapeutic Candidate which Positively Regulates and Normalizes Genes that Cause Chronic Illness CALGARY, Alberta, Sept. 13, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. […]
Apabetalone, a First-in-Class Epigenetic Therapeutic Candidate, Met Key Endpoint of Lowering Pulmonary Vascular Resistance (PVR) and Was Well Tolerated Successful Completion and Promising Results of Investigator-led APPROACH-p Trial Sets the Stage for a Larger Multicenter Trial CALGARY, Alberta, Sept. 08, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) […]
CALGARY, Alberta, July 06, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced that Ken Lebioda is stepping down as Senior Vice President, Business and Corporate Development, effective immediately. “We would like to thank Ken for his important contributions over many years of service and wish him all the […]
CALGARY, Alberta, May 05, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”) which provides for Hepalink to purchase 10% secured convertible debentures of the Company […]
Cardiovascular Publication Explores the Prespecified BETonMACE Analysis on Hospitalization for Heart Failure Following Acute Coronary Syndrome CALGARY, Alberta, Jan. 12, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone and hospitalization for heart failure in patients following an acute […]
Publication Explores the Beneficial Effects of Apabetalone on the Immune Cells of Diabetic Patients Event Reminder: Multiple Presentations on Apabetalone to be made during the American Heart Association Scientific Sessions – November 13-17 CALGARY, Alberta, Nov. 12, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “BET protein inhibitor […]
CALGARY, Oct. 14, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that Vision Leader Limited, a wholly-owned subsidiary of ORI Star Fund LP (“ORI”), has delivered a notice of conversion to convert its entire September 2019 debenture and associated interest, into Resverlogix common shares, which […]
CALGARY, Alberta, Oct. 06, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that it has entered into a definitive stock purchase agreement for a private placement of 10,560,000 equity units at a price of $1.25 per unit for gross proceeds of $13.2 million (US$10 million). […]
